Guardant Health, Inc.
For the period ended Sep 30, 2025. Filed Oct 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 29, 2025
GH$158.79+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (unaudited)
(in thousands, except share and per share data)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $580,013 | $525,540 |
| Short-term marketable debt securities | — | 314,438 |
| Accounts receivable, net | 115,585 | 110,253 |
| Inventory, net | 90,489 | 71,083 |
| Prepaid expenses and other current assets, net | 42,798 | 33,800 |
| Total current assets | 828,885 | 1,055,114 |
| Restricted cash | 109,502 | 104,215 |
| Property and equipment, net | 124,609 | 136,813 |
| Right-of-use assets, net | 163,550 | 142,265 |
| Intangible assets, net | 5,477 | 6,760 |
| Goodwill | 3,290 | 3,290 |
| Other assets, net | 41,473 | 37,152 |
| Total Assets | $1,276,786 | $1,485,609 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $20,142 | $38,551 |
| Accrued compensation | 98,209 | 83,219 |
| Accrued expenses | 71,707 | 68,345 |
| Deferred revenue | 46,861 | 35,468 |
| Total current liabilities | 236,919 | 225,583 |
| Convertible senior notes, net, principal amount of $1,090,660 and $1,150,000 as of September 30, 2025 and December 31, 2024, respectively | 1,114,594 | 1,142,547 |
| Long-term operating lease liabilities | 185,387 | 164,292 |
| Other long-term liabilities | 94,359 | 92,834 |
| Total Liabilities | 1,631,259 | 1,625,256 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ deficit: | ||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2025 and December 31, 2024 | — | — |
| Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 125,982,066 and 123,994,006 shares issued as of September 30, 2025 and December 31, 2024; and 125,005,715 and 123,994,006 shares outstanding as of September 30, 2025 and December 31, 2024, respectively | 1 | 1 |
| Treasury stock, at cost, 976,351 shares as of September 30, 2025 | (45,010) | — |
| Additional paid-in capital | 2,560,814 | 2,443,788 |
| Accumulated other comprehensive loss | (4,260) | (5,201) |
| Accumulated deficit | (2,866,018) | (2,578,235) |
| Total Stockholders’ Deficit | (354,473) | (139,647) |
| Total Liabilities and Stockholders’ Deficit | $1,276,786 | $1,485,609 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.